GA
EPZM

Greenspring Associates’s Epizyme, Inc EPZM Stock Holding History

Greenspring Associates’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-228,354
Closed -$3.67M – 15
2020
Q2 		$3.67M Buy
+228,354
New +$3.99M 2.25% 7
2019
Q3 		– Sell
-130,411
Closed -$1.64M – 19
2019
Q2 		$1.64M Buy
+130,411
New +$1.68M 0.84% 5

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Greenspring Associates's EPZM Position: Q3 2020 in Review

Greenspring Associates sold out of Epizyme, Inc (EPZM) in Q3 2020, closing a stake of 228,354 shares — an estimated $3.67M sold.

Greenspring Associates first reported a position in EPZM in Q2 2019 and held it in 2 quarters. The position peaked at $3.67M in Q2 2020. 151 funds tracked by Wall St. Rank hold EPZM as of Q3 2020.

  • Greenspring Associates reported no remaining Epizyme, Inc position as of Q3 2020 after selling out during the quarter.
  • Greenspring Associates sold 228,354 Epizyme, Inc shares in Q3 2020, an estimated $3.67M.
  • Greenspring Associates first reported a position in Epizyme, Inc in Q2 2019 and held it in 2 quarters.
  • Greenspring Associates's Epizyme, Inc position peaked at $3.67M in Q2 2020.
  • 151 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2020.

Based on Greenspring Associates's 13F filing for Q3 2020, filed 12 Nov 2020.